New and Emerging Strategies in the Treatment of Patients with Higher risk Myelodysplastic Syndromes (MDS)
|
|
- Abel Maxwell
- 5 years ago
- Views:
Transcription
1 Welcome to Managing Myelodysplastic Syndromes. My name is David Steensma. I am an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Adult Leukemia Program at Dana Farber Cancer Institute here in Boston, Massachusetts. Today, I will be discussing new and emerging strategies in the management of patients with higher risk myelodysplastic syndromes. 1
2 What exactly do we mean by higher risk myelodysplastic syndromes? Given that MDS shortens lives, that progression is unpredictable, that it affects quality of life, is there really any lower risk patient? 2
3 To illustrate that I made this graphic. What if we were to imagine all of the patients diagnosed with MDS in the U.S. this year as 100 people? We think there are probably about 30,000 patients with MDS diagnosed each year. What actually happens to those patients? 3
4 Well, it is an older patient population. So, many of the patients die with MDS but not from MDS. They die from other geriatric related conditions. Secondly, about a quarter to a third of patients will go on to progress to acute myeloid leukemia. A few of those patients, the younger ones, may be able to receive intensive chemotherapy followed by stem cell transplant with a reasonable outcome, but for most patients, the life expectancy after such a transformation is only a few months at best. Patients with MDS are anemic and repeated transfusions lead to iron overload, and although the MDS is not often attributed to the congestive heart failure or the myocardial infraction or stroke that takes the patient s life, the anemia can be a contributing factor. The most common cause of non leukemogenic death in patients with MDS is infection resulting both from neutropenia and from neutrophil dysfunction. Number two is hemorrhage. Patients die either of a bleeding complication or of bleeding complicating some other problem, and finally, a small subset of patients, currently about 6%, with MDS in the United States and Western Europe will go on to get allogeneic stem cell transplant. Of them, about 30%, 2 out of 6, will be cured. About 15 20% will die of immediate short term complications such as infection. The others will either die from more chronic complications such as chronic graft versus host disease or from relapsed disease after transplant. So, as you can see, MDS in any of its forms is a dangerous disease. 4
5 However, when we are talking about which patients are at highest risk, we use prognostic tool such as this 2012 Revised International Prognostic Scoring System or the IPSS R. The IPSS R takes into account the patient s blast proportion in the marrow, the karyotype, and the number and depth of cytopenias to generate a score between 0 and 10 points. 5
6 That score is then transformed into one of five risk groups ranging from very low, where the median survival is just above 8 years, to the very highest risk where the median survival is less than 1 year. Collectively, patients with very low and low risk are referred to as lower risk. Those with high and very high risk are referred to as higher risk. The intermediate risk, we do not really have a good category for. The old IPSS was a little bit cleaner with respect to risk groups because there were four. So, the lower two were lower risk, the upper two were higher risk, but this introduction of a fifth category, intermediate, has made that classification of lower versus higher a little bit messier, and it may be that there are other disease features that will help us know which patients in this intermediate risk group are really at higher risk than the IPSS R would predict. Importantly, these figures for median survival are for patients managed primarily with supportive care, and disease modifying therapies, such as azacitidine or stem cell transplant,can modify the patient s outcomes. 6
7 One thing that we know is that somatic genetic mutations are important prognostic factors, independent of IPSS and IPSS R. These are routinely obtained now on patients with myelodysplastic syndromes. There are a number of companies and reference laboratories that provide genetic panels and next generation sequencing, and they are relatively inexpensive. In my own institution for instance, we can do a panel of 95 genes for about $800 which is cheaper than either karyotyping or the conventional hematopathology. One of our former fellows, Rafael Bejar, published 5 years ago in the New England Journal of Medicine that one of five mutations, TP53, ETV6, ASXL1, EZH2, or RUNX1, if present, effectively increases the patient risk group by one. So, for instance, the patient with IPSS intermediate 1 risk disease who has an ASXL1 mutation behaves more like a patient with IPSS intermediate 2 risk disease. 7
8 Rafael is now extending this analysis with collaborators in many countries in the hope of developing an IPSS Rm, a Molecular Prognostic Scoring System that takes into account both clinical and pathological variables and genetic mutation testing. 8
9 More than 3,500 patients have been accrued to this thus far. Follow up data are present on more than 3,000, and more than 1,000 have already undergone genetic sequencing. 9
10 Rafael has sequenced 17 genes in 1,996 patients to date and found that in a univariate analysis, 16 of them had adverse prognostic importance, whereas one, SF3B1, which is often linked with ring sideroblast morphology, was more favorable. 10
11 However in a multivariable analysis taking into account other IPSS risk factors, the SF3B1 remained favorable, but all but four of the other unfavorable mutations fell out. The p53 mutations are prognostically the highest risk in MDS followed by RUNX1, EZH2, and NRAS. The others did not have IPSS independent effects on prognosis. 11
12 So, what about treatment? 12
13 I made this slide in 2006 and have made very few changes since. The platelet growth factors which are an off label use are increasing in their utilization in myelodysplastic syndromes, but we have not had a new drug approval since May 2006 for MDS. Hopefully, in the near future, there will be another drug approved, but that agent, luspatercept, which is currently undergoing a registration trial is for lower risk disease and not higher risk. So, we have three drugs that have a specific MDS approval, azacitidine and decitabine, the DNA methyltransferase inhibitors, and we have the immunomodulatory drug lenalidomide which is approved for patients with lower risk disease and del(5q). Iron chelators are approved for transfusion related hemosiderosis which commonly occurs in MDS. The red cell growth factors are actually the most commonly used drugs, but they do not currently have a specific label for MDS. Their approval is in chemotherapy associated anemia, renal failure, and other indications. 13
14 The azacitidine 001 study showed that AZA is the only thing when compared with conventional care, such as best supportive care alone or low dose or high dose cytotoxic chemotherapy, improves survival. The median survival improvement was 9 months in patients who received azacitidine on the AZA 001 study. Importantly, control groups for other trials in a higher risk MDS have not had a median survival of 24 months or even of 15 months, and so, this study probably enrolled a patient subset who were a little bit lower risk than a typical high risk patient. For instance, patients on this trial had been diagnosed with MDS a median of 13 months before enrollment, which is different for other high risk studies. 14
15 In the decitabine D 0007 study, there was not a survival benefit, but those patients appeared to be higher risk as manifested by the median survival in the control group, which was only about 8months. There was a delay to leukemia progression in this patient cohort. 15
16 An algorithm for how patients with MDS are to be approached is seen here, which we published in Blood back in Many patients with MDS, especially those whose cytopenias are milder do not need treatment initially and can be observed for a period of time. However, when treatment is indicated, using a tool such as the IPSS R supplemented by molecular genetic testing allows us to divide patients into lower risk and higher risk disease. We will not talk about lower risk disease today, but that is a group of patients in which lenalidomide, growth factors, immunosuppressive therapy, and sometimes hypomethylating agents are used. In the higher risk patients, the key decision is whether or not patients are candidates for allogeneic stem cell transplant. For those who are candidates, mathematical modeling has shown that getting them two transplants as quickly as possible is beneficial. For those who are not transplant candidates or do not have a donor, this is where really the hypomethylating agents are important. However, as we saw from the azacitidine study with a 24 month median survival, these are not curative agents and eventually all patients will lose response or progress, and we do not have a well established second line therapy for higher risk MDS for whom hypomethylating agents have failed. There have been several attempts to improve the outcomes for patients with higher risk disease. For instance, one strategy is to add a second agent to azacitidine or decitabine and there have been a number of studies adding either deacetylase inhibitors or lenalidomide to azacitidine as upfront therapy for higher risk MDS. Unfortunately, all those studies have been negative. However, this strategy continues to be employed and studies are ongoing looking at Seattle Genetics vadastuximab, a CD33 antibody drug conjugate, and venectoclax or ABT 199, a BCL 2 modulator, in patients with higher risk disease, adding them to the hypomethylating agent backbone. Additionally, there are a number of studies that are adding checkpoint inhibitors to that backbone or adding checkpoint inhibitors or other agents such as the PI3 kinase modulator, rigosertib, as second line therapy, and those in general are the strategies that are being employed in patients with higher risk MDS. 16
17 As mentioned, however, we now have four different studies with HDAC inhibitors, entinostat, vorinostat, pracinostat, and a French study with valproic acid which is an antiepileptic that has weak deacetylase inhibitor activity, and all four of those showed more toxicity and no increase in efficacy in the combination arm compared with azacitidine alone. Two studies have shown that lenalidomide results in more toxicity when added to azacitidine, although there is a small subset of patients who can tolerate this combination, who may do a little bit better than if they got azacitidine alone, but in most patients, this is an unworkable combination. And finally, there was just a study reported of birinapant, a SMAC mimetic, and inhibitor of an inhibitor apoptosis, an industry sponsored study, azacitidine versus azacitidine plus birinapant, that too was a negative trial. 17
18 What about the hypomethylating agent plus venetoclax? Certainly, in acute myeloid leukemia, we saw very exciting data in only 22 patients, with a complete response rate or complete response rate with incomplete count recovery of over 70% with combination therapy; much better than we would expect to see with azacitidine alone. However, the study drug had to be interrupted more than half of the time due to cytopenias. 18
19 What about SGN CD33A or vadastuximab? This was given to patients with AML who were felt to be unfit for chemotherapy as an IV every 4 weeks on the last day of standard hypomethylating agent therapy. These were an older patient group, median age 77 years. There were lots of febrile neutropenia. There were a lot of grade 3 and 4 cytopenias, but 65% of the patients achieved CR or CRI. 19
20 This is a table describing the ongoing checkpoint inhibitor trials in MDS, as you can see both CTLA 4, PD 1, and PDL 1 targeting drugs are being used with either azacitidine or in the case of durvalumab with CC 486, which is oral decitabine. 20
21 We know that once azacitidine or decitabine failed the patient, the outlook is poor. In one study of more than 400 patients for whom azacitidine had failed, the median survival for the cohort was 5.6 months and only 15% of the patients lived for 2 years. A decitabine study from MD Anderson showed similar result. In 87 patients who were failed by decitabine, their median survival was 4.3 months 21
22 There is a subset of patients who after azacitidine fails are in good shape with a relatively good performance status and can go on to get either stem cell transplant or an investigational therapy, and they tend to do a little bit better than those who just get palliative care, but the overall outlook is pretty grim for these patients once azacitidine or decitabine failed. 22
23 Rigosertib, a PI3 kinase and Polo like kinase inhibitor is being compared with best supportive care alone. In a prior randomized trial, almost 300 patients received this drug as a 72 hour infusion with each cycle, 23
24 and patients were stratified by blast count, and as you can see, there was a slight trend toward improved survival on the rigosertib group, but not a statistically significant difference. Rigosertib is now being studied in a more rigorously defined population of very high risk patients for whom HMAs have failed. 24
25 What about other approaches? So, there is a new more intense hypomethylator, guadecitabine, or SGI 110, that is being studied in elderly or unfit patients with AML. There are targeted agents out there such as IDH1 and IDH2 inhibitors for the 5 10% of patients with high risk MDS who have IDH inhibitors. We are just about to start a targeted agent trial that is focused on splicing. Splicing is the most common category mutation in MDS, and so the results of this are awaited. And vosaroxin, a DNA damaging agent has been studied in both HMA failures and acute leukemia patients. If you do not have a trial option for a patient, most patients will be treated with supportive care. If the blast proportion is increasing progressively, some investigators find low dose cytarabine or clofarabine helpful, but they do not tend to work very long. A small subset of patients may be candidates for induction therapy followed by transplant, but that is a very limited group of patients. 25
26 What about transplant? Really you should be thinking about transplant in the potentially eligible population as soon as a diagnosis of higher risk MDS is made because eventually the HMA will fail the patient. Currently as mentioned, only about 6% of patients undergo transplant even though it is the only potentially curative therapy, but many patients worry about risk and about the changes in lifestyle that are necessary for a transplant. It is unclear how we should be using hypomethylating agents around the time of transplant. Perhaps by using them appropriately, we could augment the graft versus leukemia effect without increasing graft versus host effect. 26
27 Thank you for your attention today, and I hope that this has been helpful for caring for your patients with higher risk myelodysplastic syndromes, a really difficult set of diseases, and I thank my colleagues with whom I am able to collaborate here in Boston on care of these patients. I would like to thank you for viewing this activity, and for additional resources, please view some of the other educational activities on ManagingMDS.com. 27
The Changing Face of MDS: Advances in Treatment
Thank you very much again for listening to me. We are going to be talking now in terms of therapy of MDS or The Changing Face of MDS Advances in Treatment. My name is Guillermo Garcia-Manero. I am a Professor
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationMaintaining Long-Term Efficacy in the Elderly MDS Patient with Poor Performance Status
Hi, my name is Dr. Hetty Carraway. I am a staff physician at the Taussig Cancer Institute at the Cleveland Clinic. Welcome to Managing MDS. 1 As you all are aware, many of our patients with MDS are in
More informationMyelodyplastic Syndromes Paul J. Shami, M.D.
Myelodyplastic Syndromes Paul J. Shami, M.D. Professor of Hematology, University of Utah Member, Huntsman Cancer Institute Objectives Define Myelodysplastic Syndromes (MDS) Explain how MDS are diagnosed
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationWhen Cancer Looks Like Something Else: How Does Mutational Profiling Inform the Diagnosis of Myelodysplasia?
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationMyelodysplastic Syndromes. Post-ASH meeting 2014 Marie-Christiane Vekemans
Myelodysplastic Syndromes Post-ASH meeting 2014 Marie-Christiane Vekemans Agenda New biological developments Risk assessment and prognostic factors New therapeutic options Agenda New biological developments
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationMyelodysplastic syndrome. Jeanne Palmer, MD Mayo Clinic, Arizona
Myelodysplastic syndrome Jeanne Palmer, MD Mayo Clinic, Arizona What is Myelodysplastic syndrome? A disease where the bone marrow doesn t work appropriately What does that mean?? Red blood cells Carry
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationUnderstanding & Treating Myelodysplastic Syndrome (MDS)
Understanding & Treating Myelodysplastic Syndrome (MDS) Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC Let s Look at Our
More informationLet s Look at Our Blood
Let s Look at Our Blood Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC 10,000,000,000 WBCs/day Bone Marrow: The Blood
More informationWestwood Kansas Forum November 7, 2015 Part 1 Page 1 of 13
Westwood Kansas Forum November 7, 2015 Part 1 Page 1 of 13 Speakers: Suman Kambhampati, MD Jean Ridgeway, DNP, APN, NP-C, AOCN Suman Kambhampati, MD: The purpose of today s talk is basically to give you
More informationMyelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management
Received: 2 October 2017 Accepted: 2 October 2017 DOI: 10.1002/ajh.24930 ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and
More informationChanges to the 2016 WHO Classification for the Diagnosis of MDS
Changes to the 2016 WHO Classification for the Diagnosis of MDS Welcome to Managing MDS. I am Dr. Ulrich Germing, and today, I will provide highlights from the 14th International Symposium on MDS in Valencia,
More informationOverview. Myelodysplastic Syndromes: What s on the Horizon? Molecular Mutations in MDS. Refining Risk Models. Incorporating Mutational Data
Myelodysplastic Syndromes: What s on the Horizon? Vu H. Duong, MD, MS Assistant Professor of Medicine University of Maryland July 16, 2016 Overview Refining Risk models Specific Therapeutic Areas of Need
More informationLay Summaries ASH 2017
Lay Summaries ASH 2017 Purpose of Document: This document contains a collection of lay summaries of accepted ASH 2017 abstracts from the following investigators: MDS CRC Members/Affiliates, Fellows (past
More informationWhat you need to know about MDS. The Myelodysplastic Syndromes. Stuart Goldberg MD
What you need to know about MDS The Myelodysplastic Syndromes Stuart Goldberg MD The Myelodysplastic Syndromes are a group of bone marrow failure diseases The bone marrow is the factory that makes blood
More informationMyelodysplastic syndromes post ASH Dominik Selleslag AZ Sint-Jan Brugge
Myelodysplastic syndromes post ASH 2016 Dominik Selleslag AZ Sint-Jan Brugge Why did they put MDS at the end of the meeting? Possible explanations Least fascinating disease without progress? Poor speaker?
More informationMYELODYSPLASTIC SYNDROMES: A diagnosis often missed
MYELODYSPLASTIC SYNDROMES: A diagnosis often missed D R. EMMA W YPKEMA C O N S U LTA N T H A E M AT O L O G I S T L A N C E T L A B O R AT O R I E S THE MYELODYSPLASTIC SYNDROMES DEFINITION The Myelodysplastic
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationRefining Prognosis. Overview. Low Blood Counts. Low Blood Counts. High Risk MDS and Novel Therapy: What s on the Horizon? 3/2/2016
High Risk MDS and Novel Therapy: What s on the Horizon? Rafael Bejar MD, PhD Aplastic Anemia & MDS International Foundation Regional Patient and Family Conference March 19 th, 216 Overview Refining Prognosis
More informationMYELODYSPLASTIC SYNDROMES
MYELODYSPLASTIC SYNDROMES Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra university hospital, Isfahan university of medical sciences Key Features ESSENTIALS OF DIAGNOSIS Cytopenias
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationAbout Myelodysplastic Syndromes
About Myelodysplastic Syndromes Overview and Types If you have been diagnosed with a myelodysplastic syndrome or are worried about it, you likely have a lot of questions. Learning some basics is a good
More informationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationMolecular Genetic Testing to Predict Response to Therapy in MDS
Molecular Genetic Testing to Predict Response to Therapy in MDS Rafael Bejar MD, PhD Bone Marrow Failure Disease Scientific Symposium Rockville, MD March 18 th, 2016 Overview Response Criteria Lenalidomide
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More information7/24/2017. MDS: Understanding Your Diagnosis and Current and Emerging Treatments. Hematopoiesis = Blood Cell Production
: Understanding Your Diagnosis and Current and Emerging Treatments Erica Warlick, MD Associate Professor of Medicine Division of Hematology, Oncology, and Transplantation University of MN Objectives Overview
More informationSummary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, San Diego CA
Summary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, 2016 - San Diego CA ASH 2016 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://ash.confex.com/ash/2016/webprogram/start.html
More informationDr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital
Dr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital IPSS scoring system Blood counts Bone marrow blast percentage Cytogenetics Age as a modulator of median survival IPSS Group Median Survival
More informationTreating Higher-Risk MDS. Case presentation. Defining higher risk MDS. IPSS WHO IPSS: WPSS MD Anderson PSS
Treating Higher-Risk MDS Eyal Attar, M.D. Massachusetts General Hospital Cancer Center eattar@partners.org 617-724-1124 Case presentation 72 year old man, prior acoustic neuroma WBC (X10 3 /ul) 11/08 12/08
More information39% Treated. 61% Untreated. 33% UnRx. 45% UnRx. 59% UnRx. 80% UnRx
AML in the Elderly สน น ว ส ทธ ศ กด ช ย งานประช มว ชาการกลางป สมาคมโลห ตว ทยาแห งประเทศไทย คร งท 53 25-26 ต ลาคม 2561 ณ โรงแรมเลอ เมอร เด ยน เช ยงใหม จ งหว ดเช ยงใหม 33% UnRx 45% UnRx 59% UnRx 80% UnRx
More informationASBMT MDS/MPN UPDATE
ASBMT MDS/MPN UPDATE Sunil Abhyankar, MD Professor of Medicine Medical Director, Pheresis and Cell Processing Division of Hematologic Malignancies and Cellular Therapeutics Department of Internal Medicine
More informationIPSS Modified 7/27/2011. WHO-Based Prognostic Scoring System (WPSS)
Advances in MDS Treatment: What s on the Horizon? New Prognostic Models and Therapies Jason Gotlib, MD, MS Assistant Professor of Medicine (Hematology) Stanford Cancer Center AA&MDSIF July 3, 011 WHO-Based
More informationMDS - Diagnosis and Treatments. Dr Helen Enright, Adelaide and Meath Hospital Dr Catherine Flynn, St James Hospital
MDS - Diagnosis and Treatments Dr Helen Enright, Adelaide and Meath Hospital Dr Catherine Flynn, St James Hospital Overview What is myelodysplasia? Symptoms Diagnosis and prognosis Myelodysplasia therapy
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationBuffalo, NY Forum September 9, 2017 Morning Session Page 1 of 32
Buffalo, NY Forum September 9, 2017 Morning Session Page 1 of 32 Speakers: Elizabeth A. Griffiths, MD Sheila Tighe, NP MDS Foundation: Please feel free to stay for that event as well. We have two speakers
More informationNational Horizon Scanning Centre. Azacitidine (Vidaza) for myelodysplastic syndrome. September 2007
Azacitidine (Vidaza) for myelodysplastic syndrome September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationBio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia Interim Data Update from Phase 2 Study Demonstrates Meaningful Clinical Improvement with
More information[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014
[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More informationLow Risk MDS Scoring System. Prognosis in Low Risk MDS. LR-PSS Validation 9/19/2012
Advances in MDS What s on the Horizon Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Newer Prognostic Systems Hypomethylating agent failures Newer Treatment approaches Role
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationMutational Impact on Diagnostic and Prognostic Evaluation of MDS
Mutational Impact on Diagnostic and Prognostic Evaluation of MDS Elsa Bernard, PhD Papaemmanuil Lab, Computational Oncology, MSKCC MDS Foundation ASH 2018 Symposium Disclosure Research funds provided by
More informationa resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral
More informationMyelodysplastic syndromes Impact of Biology. Lionel Adès Hopital Saint Louis Groupe Francophone des SMD. Épidémiologie
Myelodysplastic syndromes Impact of Biology Lionel Adès Hopital Saint Louis Groupe Francophone des SMD Épidémiologie Incidence : 3 à 6 / 100 000 hab. / An Prédomine chez les sujets âgés Augmentation de
More information2/10/2017. Updates in Acute Leukemia Therapy Blood Cancer Incidence in the United States, Leukemia Incidence in the Unites States, 2016
Updates in Acute Leukemia Therapy 2017 Aaron Logan, MD, PhD UCSF Division of Malignant Hematology and Blood and Marrow Transplantation aaron.logan@ucsf.edu @hemedoc Blood Cancer Incidence in the United
More informationShould lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France
Should lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France Myelodysplastic syndromes (MDS) are heterogeneous disorders that range from conditions with a
More informationTranscript. Special thanks to Dr. Mikkael Sekeres for volunteering his time and expertise with us today.
Transcript Slide 1. Welcome & Introductions Operator: Greetings and welcome to Current and Emerging Therapies for Myelodysplastic Syndromes telephone and web education program. It is now my pleasure to
More informationStrategies for Treating AML
Slide 1: Strategies for Treating AML Operator: Greetings, and welcome to the Strategies in Treating AML Telephone and Web Education Program. It is now my pleasure to introduce your moderator, Lizette Figueroa-Rivera.
More informationTreatment of low risk MDS
Treatment of low risk MDS Matteo G Della Porta Cancer Center IRCCS Humanitas Research Hospital & Humanitas University Rozzano Milano, Italy matteo.della_porta@hunimed.eu International Prognostic Scoring
More informationTable 1: biological tests in SMD
Table 1: biological tests in SMD Tests Mandatory Recommended Under validation Morphology Marrow aspirate Marrow biopsy 1 Iron staining Quantification of dysplasia WHO 2008 Classification Cytogenetics Conventional
More informationEHA 2017 Abstracts: 4 Abstracts ( 1 Oral Presentation, 2 EPosters, 1 Publication)
EHA 2017 Abstracts: 4 Abstracts ( 1 Oral Presentation, 2 EPosters, 1 Publication) ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS):
More informationMyelodysplastic Syndrome: Let s build a definition
1 MDS: Diagnosis and Treatment Update Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian Hospital Myelodysplastic
More informationASBMT MDS/MPN Update Sunil Abhyankar, MD
ASBMT MDS/MPN Update Sunil Abhyankar, MD Professor of Medicine Medical Director, Pheresis and Cell Processing Division of Hematologic Malignancies and Cellular Therapeutics Department of Internal Medicine
More informationUnderstanding AML Casey O Connell, MD Associate Professor, Jane Anne Nohl Division of Hematology Keck School of Medicine, USC
First Let s Look at Our Blood Understanding AML Casey O Connell, MD Associate Professor, Jane Anne Nohl Division of Hematology Keck School of Medicine, USC Bone Marrow: The Blood Cell Factory 10,000,000,000
More informationOutline. Case Study 5/17/2010. Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center
Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Case Study What is lower-risk MDS? Classification systems Prognosis Treatment
More informationWhat is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification
What is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification Rami Komrokji, MD Clinical Director Malignant Hematology Moffitt Cancer Center Normal Blood and Bone Marrow What is MDS Myelodysplastic
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationLa lenalidomide: meccanismo d azione e risultati terapeutici. F. Ferrara
La lenalidomide: meccanismo d azione e risultati terapeutici F. Ferrara MDS: new treatment goals Emerging treatment options expected to facilitate shift from supportive care to active therapy in MDS New
More informationMyelodysplastic Syndromes (MDS) Diagnosis, Treatments & Support
Myelodysplastic Syndromes (MDS) Diagnosis, Treatments & Support LLS Mission & Goals Our mission. Cure leukemia, lymphoma, Hodgkin s disease and myeloma, and improve the quality of life of patients and
More informationClinical Guidelines for Leukaemia and other Myeloid Disorders MDS
Clinical Guidelines for Leukaemia and other Myeloid Disorders MDS Reference Number Version Status Executive Lead(s) Name and Job Title Author(s) Name and Job Title 13-2H-106 2 Dr Helen Barker MDT Lead
More informationNew treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke
University of Groningen New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke IMPORTANT NOTE: You are advised to consult the publisher's version
More informationMDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?
101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone
More informationNational Horizon Scanning Centre. Decitabine (Dacogen) for myelodysplastic syndrome. April 2008
Decitabine (Dacogen) for myelodysplastic syndrome April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be
More informationBlast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome
RESEARCH ARTICLE Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome AJH Mrinal M. Patnaik, 1 Emnet A. Wassie, 1 Terra L. Lasho, 2 Curtis
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationIDH1 AND IDH2 MUTATIONS
Mutant Isocitrate Dehydrogenase (midh) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Recall the dose-limiting toxicity and preliminary clinical response results with 14- and 21-day extended treatment schedules of daily oral azacitidine. Apply new research
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationNavigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma
Welcome to Managing Hodgkin Lymphoma. I am Dr. John Sweetenham from Huntsman Cancer Institute at the University of Utah. In today s presentation, I will be discussing navigating treatment pathways in relapsed
More informationMolecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note
Molecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note MPEP/MPC Advice Note 2016-02 June 2016 Test evaluated: Tumour Protein p53 (TP53) Molecular Pathology Evaluation Panel
More informationMyelodysplastic syndromes
Haematology 601 Myelodysplastic syndromes The myelodysplastic syndromes are a group of disorders predominantly affecting elderly people, leading to ineffective haematopoiesis, and they have the potential
More informationPatient-Caregiver Forum Columbus, Ohio April 26, 2014 Page 1 of 54
Patient-Caregiver Forum Columbus, Ohio April 26, 2014 Page 1 of 54 Speakers: Alison R. Walker, MD Jean Ridgeway, MSN, APN, NP-C, AOCN Alison R. Walker, MD: Like I was saying, my name is Alison Walker.
More informationMyeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP
Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS
More informationNew concepts in the management of elderly patients with AML
New concepts in the management of elderly patients with AML Martha L. Arellano, MD Associate Professor of Hematology/Oncology Director, Hematology & Medical Oncology Fellowship Program Winship Cancer Institute
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationKevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias
Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias Relevant financial relationships in the past twelve months by presenter or spouse/partner. Speakers bureau: Novartis, Janssen, Gilead, Bayer The
More informationA prospective, multicenter European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes.
Protocol Synopsis Study Title A prospective, multicenter European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes. Short Title European MDS
More informationDisclosure. Study was sponsored by Karyopharm Therapeutics No financial relationships to disclose Other disclosures:
Combination of Selinexor with High-Dose Cytarabine and Mitoxantrone for Remission Induction in Acute Myeloid Leukemia is Feasible and Tolerable A Phase I Study (NCT02573363) Amy Y. Wang, Howie Weiner,
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationYour Speaker. Outline 10/2/2017. Myelodysplastic Syndromes and Myeloid Neoplasms. Introduction and classifications Epidemiology Presentation Workup
Myelodysplastic Syndromes and Myeloid Neoplasms Abdulraheem Yacoub, MD Associate Professor Of Medicine Clinical Director of Ambulatory Hematology clinics The University of Kansas Cancer Center Your Speaker
More informationMDS-004 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality
MDS-4 Study: REVLIMID (lenalidomide) versus Placebo in Myelodysplastic Syndromes with Deletion (5q) Abnormality TABLE OF CONTENTS Section 1. Executive Summary Section 2. Background Section
More informationAntibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationAcute Myeloid Leukemia Progress at last
Acute Myeloid Leukemia Progress at last Bruno C. Medeiros, MD September 9, 217 Introduction Mechanisms of leukemogenesis Emerging therapies in AML Previously untreated AML Relapsed and refractory patients
More informationBronx, New York Patient-Caregiver Forum Part 1 November 1, 2017 Page 1 of 6
Bronx, New York Patient-Caregiver Forum Part 1 November 1, 2017 Page 1 of 6 Speakers: Amit Verma, MD Aditi Shastri, MD Ira Braunschweig, MD Arun Sunny, PA Audrey Hassan: Great. That would be great. The
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Hematologic Malignancies and Stem Cell Transplantation Institute City of Hope Acute Myeloid Leukemia Gene
More informationMolecular profiling in confirming the diagnosis of early myelodysplastic syndrome
Molecular profiling of early MDS Hematopathology - March 2016 Article Molecular profiling in confirming the diagnosis of early myelodysplastic syndrome Maya Thangavelu 1,*, Ryan Olson 2, Li Li 2, Wanlong
More informationDecember 8, 2017 Atlanta, Georgia. PRESENTATIONS WILL BE AVAILABLE on the MDS Foundation website
Volume 23, Issue 2 FALL/WINTER 2017 MDS NEWS HIGHLIGHTS FROM THE GUEST EDITOR S DESK The 14th International Symposium on Myelodysplastic Syndromes: An Overview newsletter of the myelodysplastic syndromes
More informationMDS: Who gets it and how is it diagnosed?
MDS: Who gets it and how is it diagnosed? October 16, 2010 Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian
More informationMyelodysplastic Syndromes (MDS) Enhancing the Nurses Role in Management
Myelodysplastic Syndromes (MDS) Enhancing the Nurses Role in Management Christa Roe, RN, BS, OCN Malignant Hematology Department H Lee Moffitt Cancer Center & Research Tampa, Florida Agenda MDS Disease
More informationSafety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Abstract 102 Wei AH, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL,
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationAcute Myeloid Leukemia: A Patient s Perspective
Acute Myeloid Leukemia: A Patient s Perspective Patrick A Hagen, MD, MPH Cardinal Bernardin Cancer Center Loyola University Medical Center Maywood, IL Overview 1. What is AML? 2. Who gets AML? Epidemiology
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More informationThe Past, Present, and Future of Acute Myeloid Leukemia
The Past, Present, and Future of Acute Myeloid Leukemia Carter T. Davis, MD Hematology-Oncology Fellow Duke University Health System September 10, 2016 Overview Overview of Acute Myeloid Leukemia Review
More informationMyelodysplastic Syndromes: Understanding your diagnosis and current and emerging treatments
Myelodysplastic Syndromes: Understanding your diagnosis and current and emerging treatments Shyamala Navada, M.D., MSCR Assistant Professor Icahn School of Medicine at Mount Sinai Tisch Cancer Institute
More informationGuidelines for diagnosis and management of Adult Myelodysplastic Syndromes (MDS)
Guidelines for diagnosis and management of Adult Myelodysplastic Syndromes (MDS) Author: Dr A Pillai, Consultant Haematologist On behalf of the Haematology CNG Re- Written: February 2011, Version 2 Revised:
More informationEvolving Management of Myelofibrosis
Evolving Management of Myelofibrosis Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Why do we prognosticate?
More information